IL146707A0 - Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts - Google Patents

Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts

Info

Publication number
IL146707A0
IL146707A0 IL14670700A IL14670700A IL146707A0 IL 146707 A0 IL146707 A0 IL 146707A0 IL 14670700 A IL14670700 A IL 14670700A IL 14670700 A IL14670700 A IL 14670700A IL 146707 A0 IL146707 A0 IL 146707A0
Authority
IL
Israel
Prior art keywords
cyanoindol
benzofuran
carbamoyl
piperazine
butyl
Prior art date
Application number
IL14670700A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146707(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL146707A0 publication Critical patent/IL146707A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14670700A 1999-05-27 2000-05-16 Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts IL146707A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
IL146707A0 true IL146707A0 (en) 2002-07-25

Family

ID=8238153

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14670700A IL146707A0 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts
IL146707A IL146707A (en) 1999-05-27 2001-11-22 New use of –1 [–4 (–5 cyanoindole - YL – 3) butyl] - 4 - (–2 carbamoyl - benzoporn - YL - 5) - piperazine and its physiologically acceptable salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146707A IL146707A (en) 1999-05-27 2001-11-22 New use of –1 [–4 (–5 cyanoindole - YL – 3) butyl] - 4 - (–2 carbamoyl - benzoporn - YL - 5) - piperazine and its physiologically acceptable salts

Country Status (31)

Country Link
US (4) US6900212B1 (OSRAM)
EP (3) EP1185272B1 (OSRAM)
JP (2) JP4884588B2 (OSRAM)
KR (1) KR100683367B1 (OSRAM)
CN (3) CN1679577A (OSRAM)
AR (1) AR024112A1 (OSRAM)
AT (3) ATE438399T1 (OSRAM)
AU (1) AU771778B2 (OSRAM)
BR (1) BR0010948A (OSRAM)
CA (3) CA2372668C (OSRAM)
CY (2) CY1105750T1 (OSRAM)
CZ (1) CZ295623B6 (OSRAM)
DE (3) DE60030338T2 (OSRAM)
DK (3) DK1410800T3 (OSRAM)
ES (3) ES2271707T3 (OSRAM)
HK (1) HK1048444B (OSRAM)
HU (1) HU229059B1 (OSRAM)
IL (2) IL146707A0 (OSRAM)
MX (1) MXPA01012172A (OSRAM)
MY (1) MY135627A (OSRAM)
NO (2) NO322120B1 (OSRAM)
PL (3) PL199650B1 (OSRAM)
PT (3) PT1736158E (OSRAM)
RU (1) RU2237477C2 (OSRAM)
SI (2) SI1185272T1 (OSRAM)
SK (1) SK287851B6 (OSRAM)
TR (1) TR200103361T2 (OSRAM)
TW (1) TW518218B (OSRAM)
UA (1) UA74337C2 (OSRAM)
WO (1) WO2000072832A2 (OSRAM)
ZA (1) ZA200110485B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
EP1732610A2 (en) 2004-03-26 2006-12-20 Baylor University Targeted serotonin reuptake inhibitors
MX2008015226A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Derivados de 1,3,4-oxadiazol como inhibidores de dgat1.
CN101932562B (zh) 2007-12-20 2013-06-12 阿斯利康(瑞典)有限公司 作为dgat1抑制剂190的氨基甲酰基化合物
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
JP5901528B2 (ja) * 2009-11-06 2016-04-13 エスケー バイオファーマスティカルズ カンパニー リミテッド 線維筋痛症候群の治療方法
JP5836280B2 (ja) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9708300B2 (en) 2011-03-20 2017-07-18 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
SI3598971T1 (sl) 2013-01-22 2024-10-30 Vistagen Therapeutics, Inc. Odmerne oblike in terapevtske uporabe L-4-klorokinurenina
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
EA201792571A1 (ru) * 2015-05-22 2018-06-29 Вистаджен Терапьютикс, Инк. Терапевтическое применение l-4-хлорокинуренина

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612813A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetizing device with pole array, and magnetizing method
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
AU5066300A (en) 2000-12-18
PL199516B1 (pl) 2008-09-30
DE60030338T2 (de) 2007-08-16
US20080119484A1 (en) 2008-05-22
EP1736158A2 (en) 2006-12-27
CY1105750T1 (el) 2010-12-22
NO20061562L (no) 2001-11-26
UA74337C2 (uk) 2005-12-15
MXPA01012172A (es) 2002-07-22
DE60030338D1 (de) 2006-10-05
TR200103361T2 (tr) 2002-05-21
HUP0201275A2 (en) 2002-08-28
ATE263564T1 (de) 2004-04-15
HK1048444A1 (en) 2003-04-04
PL200490B1 (pl) 2009-01-30
SK287851B6 (sk) 2012-01-04
US7371756B2 (en) 2008-05-13
CA2615271C (en) 2011-02-15
NO20015746L (no) 2001-11-26
PL199650B1 (pl) 2008-10-31
PT1410800E (pt) 2007-01-31
KR20020008847A (ko) 2002-01-31
ZA200110485B (en) 2003-06-30
MY135627A (en) 2008-05-30
EP1736158A3 (en) 2007-01-03
HU229059B1 (en) 2013-07-29
JP2011148799A (ja) 2011-08-04
NO322120B1 (no) 2006-08-14
JP4884588B2 (ja) 2012-02-29
ES2330774T3 (es) 2009-12-15
CN1679577A (zh) 2005-10-12
CY1109472T1 (el) 2012-05-23
WO2000072832A2 (en) 2000-12-07
AU771778B2 (en) 2004-04-01
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
TW518218B (en) 2003-01-21
EP1410800B1 (en) 2006-08-23
EP1185272B1 (en) 2004-04-07
DK1410800T3 (da) 2006-12-27
PT1185272E (pt) 2004-08-31
HUP0201275A3 (en) 2004-04-28
HK1048444B (zh) 2005-12-09
WO2000072832A3 (en) 2001-12-20
DK1736158T3 (da) 2009-11-02
DK1185272T3 (da) 2004-08-09
CN101869565A (zh) 2010-10-27
SI1410800T1 (sl) 2007-02-28
ATE438399T1 (de) 2009-08-15
DE60009697T2 (de) 2005-04-14
BR0010948A (pt) 2002-04-23
EP1736158B1 (en) 2009-08-05
CA2694866A1 (en) 2000-12-07
DE60042710D1 (de) 2009-09-17
CA2372668A1 (en) 2000-12-07
SK16462001A3 (sk) 2002-02-05
ES2271707T3 (es) 2007-04-16
AR024112A1 (es) 2002-09-04
ATE337008T1 (de) 2006-09-15
JP2003500441A (ja) 2003-01-07
EP1410800A1 (en) 2004-04-21
US20100063062A1 (en) 2010-03-11
NO324230B1 (no) 2007-09-10
CA2615271A1 (en) 2000-12-07
CN1198618C (zh) 2005-04-27
PT1736158E (pt) 2009-11-11
SI1185272T1 (en) 2004-12-31
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
IL146707A (en) 2007-06-03
RU2237477C2 (ru) 2004-10-10
DE60009697D1 (de) 2004-05-13
CZ20014226A3 (cs) 2002-03-13
CA2372668C (en) 2009-11-03
NO20015746D0 (no) 2001-11-26
PL352373A1 (en) 2003-08-25
CZ295623B6 (cs) 2005-09-14
US7642261B2 (en) 2010-01-05
KR100683367B1 (ko) 2007-02-15
CN1361692A (zh) 2002-07-31

Similar Documents

Publication Publication Date Title
IL146707A0 (en) Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts
IL144113A0 (en) Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
NO2015009I1 (no) Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
HUP0301391A3 (en) Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
EE200100498A (et) 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
AU6392701A (en) Piperazine and piperidine compounds
MXPA04001209A (es) Farmaco con efecto neuroprotector.
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
IL121461A0 (en) Use of 1-[4-[4-aryl (or heteroaryl)-1-piperazinyl]butyl]-1H-azole derivatives
DK1055658T3 (da) Fremstilling af cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphtalen-1-yl)phenoxy]ethyl-pyrrolidin
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
AU3022201A (en) Novel use of (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)- chromane and its physiologically aceptable salts
HUP0401039A3 (en) Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
IL112661A0 (en) 1-[2-(1h-inden-3-yl) ethyl]-4-(naphth-1-yl) piperazine derivatives, their preparation and their application in therapeutics
IL154982A0 (en) Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl] piperazine hydrochloride
IL139405A0 (en) Reduced particle size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine
NZ315363A (en) 1-[2-(2,3-dihydro-1h-inden-1-yl)ethyl]-4-(naphthalen-1-yl)piperazine derivatives, preparation thereof and therapeutical use thereof
NZ308110A (en) Polymorphs of lesopitron dihydrochloride, ie 2-[4-[4-[4- (chloropyrazole-1-yl)butyl]-1-piperazinyl]pyrimidine, and its hydrated forms, preparation and pharmaceutical compositions
IL122975A0 (en) Use of 1-[6-chloro-5- (trifluoromethyl)-2-pyridinyl] piperazine
SI1436282T1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
AU2002359274A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
HUP0105124A3 (en) 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone and method for its preparation
HK1010880A (en) 1-[2-(2,3-dihydro-1h-inden-1-yl)ethyl]-4-(naphthalen-1-yl)piperazine derivatives, preparation thereof and therapeutical use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed